SPÓŁKA AKCYJNA
Orthoget
Orthoget Spółka Akcyjna
KRS: 0001200317NIP: 8992820229REGON: 367497677Share capital: 194.5 K PLN
Research and development72.10.ZScientific research and development
UL. MUCHOBORSKA, 18, 54-424, WROCŁAW, POLSKAActive
SPÓŁKA AKCYJNA
Orthoget
Orthoget Spółka Akcyjna
SPÓŁKA AKCYJNA
Orthoget Spółka Akcyjna
Orthoget Spółka Akcyjna (KRS 0001200317, NIP 8992820229) is a Polish company, headquartered in Wrocław, Dolnośląskie voivodeship. ORTHOGET operates in: Scientific research and development (PKD 72.10.Z). Industry: Research and development. The company has been listed in the National Court Register since October 16, 2025.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Other activities
HTTPS://ORTHOGET.COMFounded
October 16, 2025
0 years in operation
Legal form
SPÓŁKA AKCYJNA
Registry: RejP
Headquarters
WROCŁAW
DOLNOŚLĄSKIE
Primary PKD
72.10.Z
Scientific research and development
Share capital
194.5 K PLN
Shareholders
N/A
Board
2 people
Sup. board: 3
Filed years
N/A
Registry entries
7
latest: July 13, 2026
No KPI data - financial statements and valuation are unavailable for this company.
Rate business credibility - Orthoget.
No ratings
News
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
Answers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
ORTHOGET's board has 2 members.
Latest reporting year
2025
Available years
1
Filing entries
0
7 historical registry entries for Orthoget
Registration in the Polish National Court Register
WR.VI NS-REJ.KRS/30408/25/650
Share capital change, Articles of association amended, Change in Section 1 (basic data)
WR.VI NS-REJ.KRS/39296/25/174
Board change
WR.VI NS-REJ.KRS/7856/26/336
Filing documents submitted (4 documents)
Competing companies or those operating in the same market segment as Orthoget (in Wrocław, industry: Research and development).
WROCŁAW· Research and development
Revenue 2024: 6.4 M PLN
WROCŁAW· Research and development
Revenue 2023: 683.0 K PLN
WROCŁAW· Research and development
Revenue 2024: 0 PLN
WROCŁAW· Research and development
WROCŁAW· Research and development
Revenue 2023: 0 PLN
WROCŁAW· Research and development
